{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:08:40Z","timestamp":1791299320955,"version":"4.1.0"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pcad.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T07:04:59Z","timestamp":1763276699000},"page":"78-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP)"],"prefix":"10.1016","volume":"94","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Bielecka-Dabrowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo F.G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Dalakoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Lewek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ntaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boguslaw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pe\u0107in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Solnica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Sosnowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.pcad.2025.11.003_bb0005","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks Collaborators. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0015","article-title":"Global burden of cardiovascular diseases and risks 2023 Collaborators. Global, regional, and National Burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.33963\/v.phj.105235","article-title":"Interdisciplinary expert team statement on the treatment of multi-bed atherosclerotic disease - endorsed by polish cardiac society, polish lipid association, polish Society of Diabetology, polish neurological society","volume":"83","author":"Dyrbu\u015b","year":"2025","journal-title":"Polish Soc Nephrol Kardiol Pol"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0025","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.5114\/aoms\/171473","article-title":"Association between electronic nicotine delivery systems use and risk of stroke: a meta-analysis of 1,024,401 participants","volume":"19","author":"Awad","year":"2023","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/STROKEAHA.112.668277","article-title":"Statin therapy and outcome after ischemic stroke","volume":"44","author":"Chr\u00f3in\u00edn","year":"2013","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.pcad.2025.11.003_bb0040","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.3390\/jcm10194472","article-title":"Secondary stroke prevention in polish adults: Results from the LIPIDOGRAM2015 study","volume":"10","author":"Labuz-Roszak","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-001972","article-title":"Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment","volume":"9","author":"Gynnild","year":"2022","journal-title":"Open Heart"},{"issue":"34","key":"10.1016\/j.pcad.2025.11.003_bb0050","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC National Cardiac Societies; ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0055","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/medicina59040776","article-title":"Medical Management of Dyslipidemia for secondary stroke prevention: narrative review","volume":"59","author":"Chang","year":"2023","journal-title":"Medicina"},{"issue":"7","key":"10.1016\/j.pcad.2025.11.003_bb0060","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"37","key":"10.1016\/j.pcad.2025.11.003_bb0065","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/eurheartj\/ehab204","article-title":"The international lipid expert panel (ILEP)-the role of \u201coptimal\u201d collaboration in the effective diagnosis and treatment of lipid disorders","volume":"42","author":"Banach","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb0070","article-title":"The European Society of Cardiology Council on stroke: building the future of the multidisciplinary study of stroke","volume":"ehaf719","author":"Lip","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb0075","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"220","key":"10.1016\/j.pcad.2025.11.003_bb0080","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ijcard.2016.06.091","article-title":"What is the association of lipid levels and incident stroke?","author":"Glasser","year":"2016","journal-title":"Int J Cardiol"},{"issue":"40","key":"10.1016\/j.pcad.2025.11.003_bb0085","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","article-title":"Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) study","volume":"39","author":"Penson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb0090","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"15","key":"10.1016\/j.pcad.2025.11.003_bb0095","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"SANTORINI study investigators. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"ESC\/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.pcad.2025.11.003_bb0110","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.pcad.2025.11.003_bb0120","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5114\/aoms\/183522","article-title":"Recommendations of the experts of the polish cardiac society (PCS) and the polish lipid association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels","volume":"20","author":"Sosnowska","year":"2024","journal-title":"Arch Med Sci"},{"issue":"19","key":"10.1016\/j.pcad.2025.11.003_bb0130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/eurheartj\/ehae150","article-title":"Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on stroke, the European Association of Cardiovascular Imaging and the European heart rhythm association of the ESC","volume":"45","author":"Ntaios","year":"2024","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.pcad.2025.11.003_bb0135","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"On behalf of the HOPE-3 investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pcad.2025.11.003_bb0140","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0145","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000525672","article-title":"Statin therapy for preventing recurrent stroke in patients with ischemic stroke: A systematic review and Meta-analysis of randomized controlled trials and observational cohort studies","volume":"56","author":"Yin","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pcad.2025.11.003_bb0155","author":"Banach","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0160","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","article-title":"The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis","volume":"31","author":"Qin","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3; suppl","key":"10.1016\/j.pcad.2025.11.003_bb0165","article-title":"Efficacy and safety of Inclisiran in patients with established cerebrovascular disease: pooled post hoc analysis of the phase 3 ORION-9, ORION-10, and ORION-11 randomized controlled trials","volume":"16","author":"Ray","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.pcad.2025.11.003_bb0170","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb0180","first-page":"355","article-title":"2024: the year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings","volume":"21","author":"Sosnowska","year":"2025","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0185","author":"Langlois","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb0190","first-page":"357","article-title":"2024 guidelines of the polish Society of Laboratory Diagnostics and the polish lipid association on laboratory diagnostics of lipid metabolism disorders","volume":"20","author":"Solnica","year":"2024","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0195","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2025.11.003_bb0200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/clinchem\/hvad199","article-title":"Extensive evidence supports the Martin\u2013Hopkins Equation as the LDL-C calculation of choice","volume":"70","author":"Grant","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.pcad.2025.11.003_bb0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/clinchem\/hvad190","article-title":"The Sampson-NIH equation is the preferred calculation method for LDL-C","volume":"70","author":"Sampson","year":"2024","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0210","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0215","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"10.1016\/j.pcad.2025.11.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2827","article-title":"Lipidogram cohort studies, Remnant cholesterol and mortality in 37.559 patients from LIPIDOGRAM 2004, 2006 and 2015 studies","volume":"45","author":"Banach","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb0225","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.117.030509","article-title":"Embolic Stroke","volume":"136","author":"Ntaios","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.11.003_bb0230","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/ene.12438","article-title":"Association of ischaemic stroke subtype with long-term cardiovascular events","volume":"21","author":"Ntaios","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0235","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke: A guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb0240","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.pcad.2025.11.003_bb0245","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of Total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0250","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cvr\/cvaf045","article-title":"Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention","volume":"121","author":"Banach","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2025.11.003_bb0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2025.11.003_bb0260","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0265","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ehjcvp\/pvaf007","article-title":"Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment","volume":"11","author":"Parhofer","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.pcad.2025.11.003_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0280","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0285","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0295","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2025.11.003_bb0300","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0305","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0310","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0315","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s11357-024-01491-8","article-title":"Impact of adherence to the Mediterranean diet on stroke risk","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"},{"issue":"38","key":"10.1016\/j.pcad.2025.11.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012450","article-title":"Adherence to the dietary approaches to stop hypertension diet and risk of stroke: A meta-analysis of prospective studies","volume":"97","author":"Feng","year":"2018","journal-title":"Medicine"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0325","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40279-024-02115-z","article-title":"The effect of exercise training on blood lipids: A systematic review and meta-analysis","volume":"55","author":"Smart","year":"2025","journal-title":"Sports Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0335","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12966-024-01593-8","article-title":"Leisure-time and occupational physical activity and risk of cardiovascular disease incidence: a systematic-review and dose-response meta-analysis of prospective cohort studies","volume":"21","author":"Kazemi","year":"2024","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.pcad.2025.11.003_bb0340","doi-asserted-by":"crossref","DOI":"10.5114\/aoms\/210673","article-title":"No time to wait: daily step counts should be incorporated into physical activity guidelines","author":"Banach","year":"2025","journal-title":"Arch Med Sci"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0345","first-page":"711","article-title":"International lipid expert panel (ILEP). A 360\u00b0 perspective on cardiovascular prevention: the international lipid expert panel SiMple tIps for the heaLthy hEart (ILEP-SMILE)","volume":"21","author":"Banach","year":"2025","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0350","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0355","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0360","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0365","doi-asserted-by":"crossref","first-page":"113c","DOI":"10.1016\/S0002-9149(99)80480-9","article-title":"The west of Scotland coronary prevention study: a trial of cholesterol reduction in Scottish men","volume":"76","author":"Shepherd","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0370","doi-asserted-by":"crossref","DOI":"10.1177\/23969873221100032","article-title":"European stroke organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0375","first-page":"855","article-title":"Ezetimibe: mechanism of action and clinical update","volume":"24","author":"Ballantyne","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0380","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"International lipid expert panel (ILEP). Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the international lipid expert panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"25","key":"10.1016\/j.pcad.2025.11.003_bb0385","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pcad.2025.11.003_bb0390","first-page":"1439","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0395","first-page":"361","article-title":"RACING investigators. Moderate-intensity statin with ezetimibe vs high-intensity statin in patients with recent ischemic stroke: the RACING randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0400","article-title":"Atorvastatin plus ezetimibe for secondary prevention in ischemic stroke patients: A Nationwide cohort study","volume":"13","author":"Park","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0405","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOL.0000000000000911","article-title":"Bempedoic acid: new evidence and recommendations on use","volume":"35","author":"Paponja","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0410","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0415","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037898","article-title":"Bempedoic acid for prevention of cardiovascular events in people with obesity: A CLEAR outcomes subset analysis","volume":"14","author":"Bays","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.11.003_bb0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the international lipid expert panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"18","key":"10.1016\/j.pcad.2025.11.003_bb0425","doi-asserted-by":"crossref","first-page":"10221","DOI":"10.3390\/ijms231810221","article-title":"Recent advances on the roles of PCSK-9 inhibitors in the Management of Acute Ischemic Stroke Patients","volume":"23","author":"Ilut","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0430","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamaneurol.2020.2494","article-title":"New horizons in pharmacologic therapy for secondary stroke prevention","volume":"77","author":"Katsanos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp-2023-332392","article-title":"PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis","volume":"95","author":"Wu","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0440","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOL.0000000000000988","article-title":"Safety and effectiveness of proprotein convertase subtilisin\/kexin type 9 inhibition: an updated review","volume":"36","author":"Pamporis","year":"2025","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0445","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/13543784.2021.1985463","article-title":"Emerging agents for the treatment and prevention of stroke: progress in clinical trials","volume":"30","author":"Safouris","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0450","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp-2022-329149","article-title":"Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention","volume":"95","author":"Sagris","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.pcad.2025.11.003_bb0455","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107633","article-title":"Efficacy and safety of PCSK9 inhibitors for stroke prevention: systematic review and meta-analysis","volume":"33","author":"Moustafa","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0465","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Heart Group, editor","volume":"2020","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0470","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","article-title":"The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis","volume":"31","author":"Qin","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0475","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"issue":"06","key":"10.1016\/j.pcad.2025.11.003_bb0480","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5414\/CP204506","article-title":"Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials","volume":"62","author":"Shin","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0485","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.amjcard.2019.09.011","article-title":"Meta-analysis of randomized controlled trials assessing the impact of Proprotein convertase Subtilisin\/Kexin type 9 antibodies on mortality and cardiovascular outcomes","volume":"124","author":"AlTurki","year":"2019","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2025.11.003_bb0490","article-title":"PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety","author":"Kim","year":"2024","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0495","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.pcad.2025.11.003_bb0500","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","author":"Bohula","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","article-title":"Spectrum of mutations in Italian patients with familial hypercholesterolemia: new results from the LIPIGEN study","volume":"29","author":"Pirillo","year":"2017","journal-title":"Atheroscler Suppl"},{"issue":"14","key":"10.1016\/j.pcad.2025.11.003_bb0510","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0515","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb0520","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1158274","article-title":"Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0530","first-page":"569","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts\u2019 opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0535","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000877","article-title":"Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent","volume":"34","author":"Giordano","year":"2023","journal-title":"Curr Opin Lipidol"},{"issue":"Supplement_1","key":"10.1016\/j.pcad.2025.11.003_bb0540","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0545","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran-new hope in the management of lipid disorders?","volume":"14","author":"Dyrbu\u015b","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1449712","article-title":"Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials","volume":"16","author":"Harbi","year":"2025","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0555","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MOL.0000000000000954","article-title":"From clinical development to real-world outcomes with inclisiran","volume":"35","author":"Connolly","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0565","doi-asserted-by":"crossref","unstructured":"Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Heart Group, ed. Cochrane Database of Systematic Reviews. 2015; 2018(4). doi:https:\/\/doi.org\/10.1002\/14651858.CD009580.pub2.","DOI":"10.1002\/14651858.CD009580.pub2"},{"issue":"9500","key":"10.1016\/j.pcad.2025.11.003_bb0570","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.pcad.2025.11.003_bb0575","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0580","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0585","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5125","article-title":"Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study","author":"Kim","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0590","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-024-02353-5","article-title":"Fenofibrate\u2019s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study","volume":"23","author":"Hong","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0595","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European atherosclerosis society task force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0600","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2025.11.003_bb0610","article-title":"Reduction in ischemic stroke with Icosapent ethyl - insights from REDUCE-IT","volume":"52","author":"Bhatt","year":"2021","journal-title":"Stroke"},{"issue":"22","key":"10.1016\/j.pcad.2025.11.003_bb0615","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0620","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0625","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of Obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"10491","key":"10.1016\/j.pcad.2025.11.003_bb0630","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0635","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","article-title":"Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","volume":"274","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"25","key":"10.1016\/j.pcad.2025.11.003_bb0640","first-page":"E729","article-title":"Safety and efficacy of Obicetrapib in patients with heterozygous familial hypercholesterolemia","volume":"150","author":"Nicholls","year":"2024","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.pcad.2025.11.003_bb0645","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of Obicetrapib on major adverse cardiovascular events in high-risk patients: A pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0650","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.athplu.2024.11.003","article-title":"Emerging oral therapeutic strategies for inhibiting PCSK9","volume":"59","author":"Ferri","year":"2025","journal-title":"Atherosclerosis Plus"},{"issue":"16","key":"10.1016\/j.pcad.2025.11.003_bb0655","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the Oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.pcad.2025.11.003_bb0665","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An Oral PCSK9 inhibitor for Treatment of hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0670","series-title":"CORALreef outcomes (NCT06008756): A study of Enlicitide Decanoate (MK-0616) in Adults with Hyperlipidemia [Clinical Trial Registry]","author":"ClinicalTrials.gov","year":"2023"},{"key":"10.1016\/j.pcad.2025.11.003_bb0675","series-title":"AZURE-Outcomes (NCT07000357): A Study of AZD0780 in Patients with ASCVD or at High Risk [Clinical Trial Registry]","author":"ClinicalTrials.gov","year":"2024"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0680","first-page":"1602","article-title":"2023: the year in cardiovascular disease\u2014the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"},{"issue":"19","key":"10.1016\/j.pcad.2025.11.003_bb0685","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0690","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.pcad.2025.11.003_bb0695","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0700","doi-asserted-by":"crossref","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ., Singleton W, Hughes SG., et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med, 371(23), 2200\u20132206. doi:https:\/\/doi.org\/10.1056\/NEJMoa1400284.","DOI":"10.1056\/NEJMoa1400284"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0705","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabet Endocrinol"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb0710","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent Chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pcad.2025.11.003_bb0715","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0720","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with Olezarsen in moderate hypertriglyceridemia","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0725","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118189","article-title":"ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives","volume":"188","author":"Tamehri Zadeh","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0735","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the Treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0740","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: A phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0745","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pcad.2025.11.003_bb0750","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2025.03.005","article-title":"Effect of ANGPTL3 inhibition with Solbinsiran in preclinical and early human studies","volume":"85","author":"Ray","year":"2025","journal-title":"JACC"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0755","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.pcad.2025.11.003_bb0760","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: A randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0765","series-title":"ENTRUST (NCT05852431): A Study of Pegozafermin in Patients with Severe Hypertriglyceridemia [Clinical Trial Registry]","author":"ClinicalTrials.gov","year":"2023"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0770","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","article-title":"Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention","volume":"82","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0775","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41598-024-51310-5","article-title":"Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study","volume":"14","author":"Jang","year":"2024","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.pcad.2025.11.003_bb0780","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0785","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamacardio.2023.2731","article-title":"Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: A systematic review and updated meta-regression analysis","volume":"8","author":"Iatan","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb0790","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/medicina59111980","article-title":"Effect of combination therapy with ezetimibe and statins versus statin monotherapy on carotid intima-media thickness: A systematic review and Meta-analysis of randomized controlled trials","volume":"59","author":"Kwon","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.pcad.2025.11.003_bb0795","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/STROKEAHA.111.625186","article-title":"Common carotid artery intima-media thickness progression as a predictor of stroke in multi-ethnic study of atherosclerosis","volume":"42","author":"Polak","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb0800","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2004","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0805","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurjpc\/zwae081","article-title":"Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study, European journal of","volume":"31","author":"Jun","year":"2024","journal-title":"Prev Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb0810","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1007\/s12325-021-01892-7","article-title":"Adherence to lipid-lowering Treatment by single-pill combination of statin and ezetimibe","volume":"38","author":"Rea","year":"2021","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0815","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res sierpie\u0144"},{"key":"10.1016\/j.pcad.2025.11.003_bb0820","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb0825","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.pcad.2025.11.003_bb0830","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3390\/jcm14092990","article-title":"Lipoprotein(a) as a stroke biomarker: pathophysiological pathways and therapeutic implications","volume":"14","author":"Panagiotopoulos","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0835","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0840","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and incident ischemic stroke: the atherosclerosis risk in communities (ARIC) study","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb0845","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1178079","article-title":"Lipoprotein(a) and stroke: a two-sample Mendelian randomization study","volume":"15","author":"Huang","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107960","article-title":"Association of elevated lipoprotein(a) levels with ischemic stroke in young patients - a systematic review and meta-analysis","volume":"33","author":"Koh","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pcad.2025.11.003_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119231","article-title":"Residual lipoprotein(a)-associated risk in patients with stroke or transient ischemic attack","volume":"405","author":"Hoshino","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0860","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0865","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/STROKEAHA.121.034924","article-title":"Effect of lipoprotein(a) on stroke recurrence attenuates at low LDL-C (low-density lipoprotein) and inflammation levels","volume":"53","author":"Xu","year":"2022","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0711","article-title":"The correlation between lipoprotein(a) and cognitive impairment in patients with ischemic stroke","volume":"86","author":"Zhang","year":"2025","journal-title":"Br J Hosp Med"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb0875","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5853\/jos.2024.04623","article-title":"The Association of Lipoprotein(a) and stroke recurrence: A systematic review and Meta-analysis","volume":"27","author":"Palaiodimou","year":"2025","journal-title":"J Stroke"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0880","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16501","article-title":"Impact of elevated lipoprotein(a) levels on the functional outcomes of ischemic stroke patients: A systematic review and meta-analysis","volume":"31","author":"Liu","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0885","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2147\/DMSO.S502459","article-title":"Lipoprotein(a) as a risk factor for recurrent ischemic stroke in type 2 diabetes","volume":"18","author":"Chen","year":"2025","journal-title":"Diabetes Metab Syndr Obes maj"},{"key":"10.1016\/j.pcad.2025.11.003_bb0890","series-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"Vol. 42(1)","author":"Reyes-Soffer","year":"2022"},{"issue":"3","key":"10.1016\/j.pcad.2025.11.003_bb0895","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0900","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.3390\/jcm14196713","article-title":"The Association of Lipoprotein(A) and coronary artery calcium in primary prevention patients\u2014data from the STAR-Lp(A) study","volume":"14","author":"Burzy\u0144ska","year":"2025","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb0905","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/ph15121573","article-title":"Targeted treatment against Lipoprotein (a): The coming breakthrough in lipid lowering therapy","volume":"15","author":"Sosnowska","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb0910","first-page":"1770","article-title":"Lp(a) and thromboembolism: current state of knowledge and unsolved issues","volume":"20","author":"Konieczy\u0144ska","year":"2024","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms\/183608","article-title":"Rosuvastatin-based combination Treatment with acetylsalicylic acid or ezetimibe in the Management of Patients at high and very high cardiovascular risk. Expert opinion paper of the polish lipid association 2025","volume":"21","author":"Banach","year":"2025","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0920","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with Pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0925","article-title":"Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050","volume":"38","author":"Wafa","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.pcad.2025.11.003_bb0930","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial","volume":"320","author":"Iso","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb0935","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190878","article-title":"Location, number and factors associated with cerebral microbleeds in an Italian-British cohort of CADASIL patients","volume":"13","author":"Nannucci","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pcad.2025.11.003_bb0940","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/STROKEAHA.120.029345","article-title":"Impact of statins on hematoma, edema, seizures, vascular events, and functional recovery after intracerebral hemorrhage","volume":"52","author":"Spr\u00fcgel","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb0945","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the stroke prevention by aggressive reduction in Cholesterol levels (SPARCL) trial","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb0950","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0955","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"issue":"20","key":"10.1016\/j.pcad.2025.11.003_bb0960","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb0965","first-page":"912","article-title":"Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988)","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2025.11.003_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105655","article-title":"LDL-C levels below 55 mg\/dl and risk of hemorrhagic stroke: A Meta-analysis","volume":"30","author":"Masson","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pcad.2025.11.003_bb0975","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of Alirocumab on stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.11.003_bb0980","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb0985","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eclinm.2019.02.007","article-title":"Statins and risk of intracerebral Haemorrhage in a stroke-free population: A Nationwide Danish propensity score matched cohort study","volume":"8","author":"Ribe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pcad.2025.11.003_bb0990","article-title":"The double-edged sword of statins in intracerebral hemorrhage patients: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb0995","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/STROKEAHA.111.645978","article-title":"Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage","volume":"43","author":"Dowlatshahi","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb1000","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaneurol.2014.2124","article-title":"Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition","volume":"71","author":"Flint","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/cns.12274","article-title":"Use of statin during hospitalization improves the outcome after intracerebral hemorrhage","volume":"20","author":"Pan","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pcad.2025.11.003_bb1010","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000008627","article-title":"Statins for neuroprotection in spontaneous intracerebral hemorrhage","volume":"93","author":"Chen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2025.11.003_bb1015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/JMDH.S297299","article-title":"Left ventricular diastolic dysfunction as predictor of unfavorable prognosis after ESUS","volume":"9","author":"Bielecka-Dabrowa","year":"2021","journal-title":"J Multidiscip Healthc"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb1020","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1161\/STROKEAHA.119.026992","article-title":"Use of statins after ischemic stroke in young adults and its association with Long-term outcome","volume":"50","author":"van Dongen","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2025.11.003_bb1025","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1161\/STROKEAHA.120.030089","article-title":"Deintensification or no statin Treatment is associated with higher mortality in patients with ischemic stroke or transient ischemic attack","volume":"52","author":"Dearborn-Tomazos","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107469","article-title":"Effectiveness of statins on outcomes of patients with embolic stroke of undetermined source (ESUS)","volume":"33","author":"Vitturi","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11739-021-02743-7","article-title":"Statin treatment and outcomes after embolic stroke of undetermined source","volume":"16","author":"Sagris","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb1040","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1007\/s00415-022-11277-7","article-title":"A score to predict the stroke recurrence of patients with embolic stroke of undetermined source","volume":"269","author":"Jing","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5853\/jos.2022.02306","article-title":"Diabetes and stroke: what are the connections?","volume":"25","author":"Mosenzon","year":"2023","journal-title":"J Stroke"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb1050","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2337\/db21-0302","article-title":"Impact of lower versus higher LDL Cholesterol targets on cardiovascular events after ischemic stroke in patients with diabetes","volume":"70","author":"Amarenco","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.pcad.2025.11.003_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117313","article-title":"Lipid-lowering in diabetes: An update","volume":"394","author":"Chait","year":"2024","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pcad.2025.11.003_bb1060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb1065","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.eprac.2025.07.014","article-title":"American association of clinical endocrinology consensus statement: algorithm for management of adults with dyslipidemia. 2025 update","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.pcad.2025.11.003_bb1070","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb1075","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020219","article-title":"Lipid disorders management strategies (2024) in Prediabetic and diabetic patients","volume":"17","author":"Gaita","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pcad.2025.11.003_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109980","article-title":"Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes","volume":"190","author":"Neves","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.11.003_bb1085","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","article-title":"Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis","volume":"76","author":"Kitagawa","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","article-title":"Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial","volume":"382","author":"Benavente","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb1095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164608","article-title":"Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot \u2018prevention of decline in cognition after stroke trial\u2019 (PODCAST) randomised controlled trial","volume":"12","author":"Bath","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1100","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2214-109X(25)00013-0","article-title":"Co-occurrence patterns and related risk factors of ischaemic heart disease and ischaemic stroke across 203 countries and territories: a spatial correspondence and systematic analysis","volume":"13","author":"An","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.pcad.2025.11.003_bb1105","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.pcad.2025.11.003_bb1110","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.pcad.2025.11.003_bb1115","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.pcad.2025.11.003_bb1120","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.11.003_bb1125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2025.04.028","article-title":"Incidence and risk of heart failure in patients with coronary heart disease and stroke: A population-based cohort study","volume":"250","author":"Liu","year":"2025","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.pcad.2025.11.003_bb1130","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038619","article-title":"Cardiac complications (arrhythmias and heart failure) in patients with ischemic stroke: A meta-analysis","volume":"103","author":"Shah","year":"2024","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1135","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1161\/STROKEAHA.121.037316","article-title":"Stroke-heart syndrome: incidence and clinical outcomes of cardiac complications following stroke","volume":"53","author":"Buckley","year":"2022","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036707","article-title":"Heart failure is associated with increased stroke severity, in-hospital mortality, major adverse cardiovascular events, and complications: insights from the Chinese stroke center Alliance","volume":"14","author":"Hu","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb1145","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ejheart.2005.09.005","article-title":"A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics","volume":"7","author":"Kjekshus","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"9645","key":"10.1016\/j.pcad.2025.11.003_bb1150","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pcad.2025.11.003_bb1155","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","volume":"54","author":"Cleland","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb1160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis","volume":"18","author":"Bielecka-Dabrowa","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"36","key":"10.1016\/j.pcad.2025.11.003_bb1170","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"31","key":"10.1016\/j.pcad.2025.11.003_bb1175","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.2174\/1381612822666160701073452","article-title":"Lipids, statins and heart failure: An update","volume":"22","author":"Katsiki","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.pcad.2025.11.003_bb1180","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/jnnp-2024-335110","article-title":"Increased risk of recurrent stroke in patients with impaired kidney function: results of a pooled analysis of individual patient data from the MICON international collaboration","volume":"96","author":"Molad","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jnnp-2019-320526","article-title":"Disentangling the multiple links between renal dysfunction and cerebrovascular disease","volume":"91","author":"Kelly","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.pcad.2025.11.003_bb1190","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"issue":"9678","key":"10.1016\/j.pcad.2025.11.003_bb1195","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Collins","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb1200","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2022","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.pcad.2025.11.003_bb1205","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1185\/03007995.2013.779237","article-title":"Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials","volume":"29","author":"Nikolic","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pcad.2025.11.003_bb1215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res"},{"issue":"17","key":"10.1016\/j.pcad.2025.11.003_bb1220","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jacc.2020.03.015","article-title":"Atorvastatin reduces first and subsequent vascular events across vascular territories: the SPARCL trial","volume":"75","author":"Szarek","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb1225","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"2023","author":"Tunnicliffe","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.pcad.2025.11.003_bb1230","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pcad.2025.11.003_bb1235","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of Evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb1240","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1245","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12882-025-04347-1","article-title":"Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease","volume":"26","author":"Tang","year":"2025","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2025.11.003_bb1255","first-page":"20","article-title":"Economic costs of dementia in 11 countries in Europe: estimates from nationally representative cohorts of a panel study","author":"Meijer","year":"2022","journal-title":"Lancet Reg Health \u2013 Europe"},{"key":"10.1016\/j.pcad.2025.11.003_bb1260","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","article-title":"Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association","volume":"43","author":"Goldstein","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1265","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5607\/en.2019.28.5.554","article-title":"Cholesterol metabolism in the brain and its association with Parkinson\u2019s disease","volume":"28","author":"Jin","year":"2019","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1270","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/brain\/awaf068","article-title":"The blood-brain barrier: a help and a hindrance","volume":"148","author":"Rust","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.pcad.2025.11.003_bb1275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-2012-112090","article-title":"Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-\u03b2 peptide accumulation","volume":"30","author":"Saint-Pol","year":"2012","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.pcad.2025.11.003_bb1280","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fnagi.2014.00093","article-title":"The low-density lipoprotein receptor-related protein 1 and amyloid-\u03b2 clearance in Alzheimer\u2019s disease","volume":"6","author":"Kanekiyo","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.pcad.2025.11.003_bb1285","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.645646","article-title":"Lipid transport and metabolism at the blood-brain Interface: implications in health and disease","volume":"12","author":"Pifferi","year":"2021","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1290","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41398-025-03550-w","article-title":"Fueling the brain - the role of apolipoprotein E in brain energy metabolism and its implications for Alzheimer\u2019s disease","volume":"15","author":"Budny","year":"2025","journal-title":"Transl Psychiatry"},{"issue":"9992","key":"10.1016\/j.pcad.2025.11.003_bb1295","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb1300","article-title":"Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease","author":"Davidson","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.pcad.2025.11.003_bb1305","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1592\/phco.23.6.726.32184","article-title":"The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies","volume":"23","author":"Etminan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pcad.2025.11.003_bb1310","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1038\/s41598-018-24248-8","article-title":"Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.11.003_bb1315","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000503105","article-title":"Association between use of statin and risk of dementia: A Meta-analysis of observational studies","volume":"54","author":"Poly","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pcad.2025.11.003_bb1320","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacl.2020.10.007","article-title":"Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies","volume":"15","author":"Adhikari","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1325","article-title":"Statin use and dementia risk: A systematic review and updated meta-analysis","volume":"11","author":"Westphal Filho","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.pcad.2025.11.003_bb1330","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","article-title":"Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies","volume":"29","author":"Olmastroni","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13195-023-01360-0","article-title":"Statins and cognitive decline in patients with Alzheimer\u2019s and mixed dementia: a longitudinal registry-based cohort study","volume":"15","author":"Petek","year":"2023","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.pcad.2025.11.003_bb1340","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.11.003_bb1345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. Results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1350","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006901","article-title":"Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial)","volume":"6","author":"Kato","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.11.003_bb1360","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb1365","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled safety analysis of Evolocumab in over 6000 patients from double-blind and open-label extension studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.11.003_bb1370","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1177\/0271678X17714655","article-title":"An endothelial link between the benefits of physical exercise in dementia","volume":"37","author":"Trigiani","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1016\/j.pcad.2025.11.003_bb1375","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"issue":"34","key":"10.1016\/j.pcad.2025.11.003_bb1385","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb1390","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jcsm.12344","article-title":"Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions","volume":"9","author":"Penson","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"47","key":"10.1016\/j.pcad.2025.11.003_bb1395","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1093\/eurheartj\/ehab358","article-title":"Nocebo\/drucebo effect in statin-intolerant patients: an attempt at recommendations","volume":"42","author":"Penson","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.pcad.2025.11.003_bb1400","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/eurheartj\/ehac556","article-title":"Individualized therapy in statin intolerance: the key to success","volume":"44","author":"Banach","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb1405","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.pcad.2025.11.003_bb1410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325293","article-title":"Statin adherence improves with age and subsequent treatment sequences: A retrospective cohort study using proportion of days covered (PDC)","volume":"20","author":"Tichop\u00e1d","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb1415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/jcm14020493","article-title":"Therapeutic inertia in dyslipidemia Management for Secondary Cardiovascular Prevention: results from the Italian ITACARE-P network","volume":"14","author":"Faggiano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.11.003_bb1420","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1016\/j.jacl.2024.07.005","article-title":"Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial","volume":"18","author":"Lee","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1425","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14740338.2019.1615053","article-title":"Muscle and statins: from toxicity to the nocebo effect","volume":"18","author":"Pedro-Botet","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb1430","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/CIR.0000000000001162","article-title":"Shared decision-making and cardiovascular health: A scientific statement from the American Heart Association","volume":"148","author":"Dennison Himmelfarb","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.11.003_bb1435","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0749-3797(02)00415-4","article-title":"Evaluating primary care behavioral counseling interventions: an evidence-based approach","volume":"22","author":"Whitlock","year":"2002","journal-title":"Am J Prev Med"},{"issue":"11","key":"10.1016\/j.pcad.2025.11.003_bb1440","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1161\/STROKEAHA.124.048189","article-title":"Incidence and outcomes of patients with early cardiac complications after intracerebral hemorrhage: a report from VISTA","volume":"55","author":"Ishiguchi","year":"2024","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1445","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/23969873241264115","article-title":"Stroke-heart syndrome: incidence and clinical outcomes of cardiac complications following intracerebral haemorrhage","volume":"10","author":"Hoad","year":"2025","journal-title":"Eur Stroke J"},{"issue":"12","key":"10.1016\/j.pcad.2025.11.003_bb1450","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1474-4422(18)30336-3","article-title":"Stroke-heart syndrome: clinical presentation and underlying mechanisms","volume":"17","author":"Scheitz","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pcad.2025.11.003_bb1455","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf388","article-title":"International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study","author":"Brandts","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"23","key":"10.1016\/j.pcad.2025.11.003_bb1460","article-title":"Mortality risk in patients with cardiac complications following ischemic stroke: A report from the virtual international stroke trials archive","volume":"13","author":"Ishiguchi","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.pcad.2025.11.003_bb1465","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/23969873241293573","article-title":"Incident dementia in ischaemic stroke patients with early cardiac complications: A propensity-score matched cohort study","volume":"10","author":"Bucci","year":"2025","journal-title":"Eur Stroke J"},{"issue":"26","key":"10.1016\/j.pcad.2025.11.003_bb1470","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/eurheartj\/ehac245","article-title":"Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the ESC Council on stroke","volume":"43","author":"Lip","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1475","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/23969873241274213","article-title":"Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: A propensity-matched analysis of a global federated health database","volume":"10","author":"Choi","year":"2025","journal-title":"Eur Stroke J"},{"issue":"1","key":"10.1016\/j.pcad.2025.11.003_bb1480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5334\/gh.1430","article-title":"Integrated care using the ABCstroke pathway improves cardiovascular outcomes and survival in patients with first-ever Ischaemic stroke","volume":"20","author":"Tsang","year":"2025","journal-title":"Glob Heart"},{"key":"10.1016\/j.pcad.2025.11.003_bb1485","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejim.2023.12.010","article-title":"Adherence to an integrated care pathway for stroke is associated with lower risk of major cardiovascular events: A report from the Athens stroke registry","volume":"122","author":"Sagris","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:14:37Z","timestamp":1773951277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":294,"alternative-id":["S0033062025001665"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.11.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP)","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}